Kymera Therapeutics, Inc. (KYMR) earnings

KYMR earnings moved a median of +0.30% by the close. Quarterly and annual KYMR reports and results, each read against the price at its own news timestamp. Back to the KYMR overview →

30 measured KYMR earnings events.

Where these KYMR earnings landedvs 30 measured KYMR earnings reactions
KYMR earningsMiddle 50% · -3.46% to +2.15%Zero: 0.00%Median: +0.30%Median +0.30%-5.00%0+5.00%
Middle 50% of KYMR earnings reactions-3.46% to +2.15%
Median reaction (to close)+0.30%
Measured reactions30
Point-in-time · zero look-ahead

Half of the 30 KYMR earnings events with a measured close landed between -3.46% and +2.15%; 53% closed up.

DateHeadlineEvent5-minTo close
Form 10-Q Kymera Therapeutics, For: Sep 30SEC filing · Form 10-Q-1.69%-3.46%
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer TrialPress release-1.69%-3.46%
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026Press release-1.05%-0.08%
Form 10-Q Kymera Therapeutics, For: Jun 30SEC filing · Form 10-Q+0.67%+0.59%
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business UpdatePress release+0.67%+0.59%
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026Press release+0.49%+0.24%
Form 10-Q Kymera Therapeutics, For: Mar 31SEC filing · Form 10-Q-1.11%-5.06%
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business UpdatePress release-1.11%-5.06%
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026Press release+0.94%-1.91%
Form 10-K Kymera Therapeutics, For: Dec 31SEC filing · Form 10-K+5.92%+10.50%
Form 10-Q Kymera Therapeutics, For: Sep 30SEC filing · Form 10-Q+7.56%+7.37%
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business UpdatePress release+7.56%+7.37%
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025Press release+0.45%+2.29%
Form 10-Q Kymera Therapeutics, For: Jun 30SEC filing · Form 10-Q-1.25%-1.26%
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business UpdatePress release-1.25%-1.26%
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025Press release-0.17%+1.46%
Form 10-Q Kymera Therapeutics, For: Mar 31SEC filing · Form 10-Q-1.62%-10.61%
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business UpdatePress release-1.62%-10.61%
Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025Press release+0.52%+9.14%
Form 10-K Kymera Therapeutics, For: Dec 31SEC filing · Form 10-K+1.06%-10.05%
Form 10-Q Kymera Therapeutics, For: Sep 30SEC filing · Form 10-Q+0.94%+3.17%
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business UpdatePress release+0.94%+3.17%
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31Press release+1.66%+1.06%
Form 10-Q Kymera Therapeutics, For: Jun 30SEC filing · Form 10-Q-2.00%-11.33%
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business UpdatePress release-2.00%-11.33%
Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7Press release-0.71%+5.92%
Form 10-Q Kymera Therapeutics, For: Mar 31SEC filing · Form 10-Q-1.82%+0.36%
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business UpdatePress release-1.82%+0.36%
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2Press release-1.57%-2.71%
Form 10-K Kymera Therapeutics, For: Dec 31SEC filing · Form 10-K+1.31%+1.73%
That’s how KYMR usually reacts to earnings — get an email when it moves on news →
Keep exploring

More KYMR: analyst actions → · SEC filings → · KYMR overview →